Bay Area Lyme Basis announces Emerging Head Award for promising scientist in Lyme research The Bay Area Lyme Base today announced the first annual Bay Area Lyme Base 'Emerging Head Award' and a $100,000 grant which is directed at a promising scientist who embodies the continuing future of leadership in Lyme disease analysis. Applicants must be associated with an academic, industry or research organization www.silagra100rx.com http://silagra100rx.com . Our objective is to create Lyme disease easy to diagnose and easy to cure, highlights Bonnie Crater, vice president of Bay Region Lyme Foundation's Panel of Directors and the first choice of its study and science team. We anticipate recognizing and helping an up-and-arriving scientist whose function will accelerate medical breakthroughs because of this overlooked disease.
Large Dosage HD therapy is connected with improvements in survival and clinically essential health procedures, including health-related standard of living, compared with CHD.. today announced completion of CE marking in European countries for the VIVIA hemodialysis system, made to deliver more regular, extended duration, short daily or nocturnal house HD therapy, known as High Dosage HD therapy. ''Globally, significantly less than 1 % of the estimated 1.9 million patients requiring hemodialysis execute High Dosage HD therapy currently,'' stated Bruce Culleton, M.D., senior medical director, Baxter. ''VIVIA allows a lot more hemodialysis patients usage of High Dosage HD therapy within their home environment.'' VIVIA was created with the individual as the principal operator.